Curida, an Oslo, Norway-based integrated contract development and manufacturing organization (“CDMO”), received an equity investment from Signet Healthcare Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position.
Curida is an integrated Contract Development and Manufacturing Organization (“CDMO”) specializing in the use of blow-fill-seal (“BFS”) and nasal spray technologies, as well as antibody manufacturing. It provides outsourced development and manufacturing of aseptic and non-aseptic liquid BFS and nasal spray formatted drugs, and serves the diagnostics industry with monoclonal antibodies. Its customer base ranges from small to medium-sized pharmaceutical, medical devices, and biotech companies, delivering solutions in drug development and GMP manufacturing globally.
Additionally, the Board has appointed Anders Larsson, the Company’s Chief Operating Officer, as Chief Executive Officer, effective May 1st, 2024.
FinSMEs
17/04/2024